Compare Stocks: OCUL, BLTE, LNTH, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$167.21 -4.6%	$164.49	$68.21 ▼ $200.00	$6.73B	-1.23	193,745 shs	73,267 shs
LNTH Lantheus	$99.99 0.0%	$101.60	$49.67 ▼ $111.86	$6.53B	-0.03	1.09 million shs	471,431 shs
LQDA Liquidia	$67.74 -1.3%	$75.93	$21.15 ▼ $93.61	$6.06B	0.53	1.72 million shs	423,521 shs
OCUL Ocular Therapeutix	$9.85 -6.2%	$9.89	$6.23 ▼ $16.44	$2.16B	0.97	3.94 million shs	1.02 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+1.12%	+3.49%	+8.87%	+16.30%	+145.97%
LNTH Lantheus	-0.28%	-0.72%	+0.03%	-4.63%	+99.56%
LQDA Liquidia	+3.33%	+4.44%	+0.03%	-9.13%	+199.74%
OCUL Ocular Therapeutix	+5.11%	+3.04%	-5.23%	+6.99%	-13.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$167.21 -4.6%	$164.49	$68.21 ▼ $200.00	$6.73B	-1.23	193,745 shs	73,267 shs
LNTH Lantheus	$99.99 0.0%	$101.60	$49.67 ▼ $111.86	$6.53B	-0.03	1.09 million shs	471,431 shs
LQDA Liquidia	$67.74 -1.3%	$75.93	$21.15 ▼ $93.61	$6.06B	0.53	1.72 million shs	423,521 shs
OCUL Ocular Therapeutix	$9.85 -6.2%	$9.89	$6.23 ▼ $16.44	$2.16B	0.97	3.94 million shs	1.02 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+1.12%	+3.49%	+8.87%	+16.30%	+145.97%
LNTH Lantheus	-0.28%	-0.72%	+0.03%	-4.63%	+99.56%
LQDA Liquidia	+3.33%	+4.44%	+0.03%	-9.13%	+199.74%
OCUL Ocular Therapeutix	+5.11%	+3.04%	-5.23%	+6.99%	-13.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.64	Moderate Buy	$218.73	30.81% Upside
LNTH Lantheus	2.29	Hold	$108.11	8.13% Upside
LQDA Liquidia	2.45	Hold	$98.08	44.80% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	161.55% Upside

Current Analyst Ratings Breakdown

Latest OCUL, BLTE, LNTH, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/10/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$214.00 ➝ $245.00
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.56B	4.19	$6.37 per share	15.70	$16.43 per share	6.09
LQDA Liquidia	$158.32M	38.30	N/A	N/A	$0.51 per share	132.82
OCUL Ocular Therapeutix	$51.95M	41.62	N/A	N/A	$3.07 per share	3.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	183.74	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.15	18.31	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	49.42	15.47	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)

Latest OCUL, BLTE, LNTH, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12
OCUL Ocular Therapeutix	0.14	13.10	13.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%
OCUL Ocular Therapeutix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	216	89.51 million	66.60 million	Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable

OCUL, BLTE, LNTH, and LQDA Headlines

Recent News About These Companies

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

September 23 at 7:31 AM | insidermonkey.com

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

September 23 at 7:26 AM | finance.yahoo.com

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success

September 22 at 11:01 PM | marketbeat.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 18, 2026 | globenewswire.com

Chardan Capital Reaffirms "Buy" Rating for Ocular Therapeutix (NASDAQ:OCUL)

September 18, 2026 | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from HC Wainwright

September 18, 2026 | americanbankingnews.com

Ocular Therapeutix's (OCUL) Buy Rating Reiterated at Chardan Capital

September 16, 2026 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Receives "Buy" Rating from HC Wainwright

September 16, 2026 | marketbeat.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Average Recommendation of "Moderate Buy" by Brokerages

September 16, 2026 | americanbankingnews.com

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 16, 2026 | marketbeat.com

Which Is a Better Investment, Ocular Therapeutix, Inc. or Trulieve Cannabis Corp. Stock?

September 15, 2026 | aaii.comA

Ocular Therapeutix Plans to File Eye Disease Drug Marketing Application in Q4

September 15, 2026 | finance.yahoo.com

Ocular Therapeutix Reports Positive Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD

September 15, 2026 | rttnews.com

Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD

September 15, 2026 | globenewswire.com

Ocular Therapeutix (NASDAQ:OCUL) Shares Down 7.6% - Here's What Happened

September 10, 2026 | marketbeat.com

Squarepoint Ops LLC Increases Holdings in Ocular Therapeutix, Inc. $OCUL

September 10, 2026 | marketbeat.com

Ocular Therapeutix, Inc. $OCUL Shares Purchased by Second Line Capital LLC

September 8, 2026 | marketbeat.com

Legal & General Group Plc Takes $1.16 Million Position in Ocular Therapeutix, Inc. $OCUL

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes Position in Ocular Therapeutix, Inc. $OCUL

September 5, 2026 | marketbeat.com

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

September 3, 2026 | insidermonkey.com

229,256 Shares in Ocular Therapeutix, Inc. $OCUL Bought by The Manufacturers Life Insurance Company

September 3, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, BLTE, LNTH, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

$167.20 -8.15 (-4.64%)

As of 02:55 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$99.99 -0.01 (-0.01%)

As of 02:55 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$67.74 -0.90 (-1.31%)

As of 02:56 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Ocular Therapeutix NASDAQ:OCUL

$9.85 -0.66 (-6.24%)

As of 02:56 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, BLTE, LNTH, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, BLTE, LNTH, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, BLTE, LNTH, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, BLTE, LNTH, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, BLTE, LNTH, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, BLTE, LNTH, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, BLTE, LNTH, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, BLTE, LNTH, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools